Liquid Biopsy with Surface Plasmon Resonance Biosensors

A special issue of Biosensors (ISSN 2079-6374). This special issue belongs to the section "Nano- and Micro-Technologies in Biosensors".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 4364

Special Issue Editors


E-Mail Website
Guest Editor
Faculty of Chemical Technology, Poznan University of Technology, 60-965 Poznan, Poland
Interests: biosensors; surface plasmon resonance; liquid biopsy; biomarkers; cancer markers
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Bioanalysis Laboratory, Faculty of Chemistry, University of Bialystok, Ciolkowskiego 1K, 15-245 Bialystok, Poland
Interests: biosensors; surface plasmon resonance; immunosensors; liquid biopsy; biomarkers; cancer markers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Liquid biopsy is used for medical diagnosis based on the determination of disease markers in body fluids. Body fluids such as urea, blood, saliva and cerebrospinal fluid carry a huge stream of information, via which we can gain access to a given set of biomarkers and suitable methods for their determination. The diagnosis of various kinds of cancer, cardiovascular and neurodegenerative diseases, as well as viral and bacterial infections—including the determination of the stage of the disease and the effectiveness of medical treatment—is then made much easier,.

Surface plasmon resonance (SPR) techniques offer huge potential in the determination of biomarkers.

These techniques offer label-free determination, simple biosensor construction, and direct biosensor determination. SPR techniques are also useful in the search for new biomarkers, and can be better alternatives to existing methods. The aim of this issue is to serve as a platform, bringing together researchers working on the boundary between SPR and medical diagnosis. Articles may include, but are not limited to, the following topics:

  • Biomarkers in body fluids as determined by SPR
  • Cancer detection by SPR biosensors
  • Markers for cardiovascular disease determination by SPR
  • SPR biosensors for neurodegenerative marker detection
  • Virus detection by SPR biosensors
  • New biomarkers discovered with SPR
  • Successful diagnostic applications of SPR
  • SPR for personalized diagnosis
  • Biomarker detection by localized SPR
  • SPR signal enhancement for biomarker determination
  • SPR vs. related techniques (e.g., SERS, quartz microbalance, interferometry) in diagnosis

Prof. Dr. Zenon Lukaszewski
Prof. Dr. Ewa Gorodkiewicz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liquid biopsy
  • SPR biosensors
  • SPR immunosensors
  • biomarkers by SPR
  • molecular cancer markers
  • virus detection
  • SPR for personalized diagnosis
  • localized SPR
  • SPR signal enhancement

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 764 KiB  
Article
A Comparison of Various Chips Used for the Manufacture of Biosensors Applied in Non-Fluidic Array SPRi, Based on the Example of Determination of Cathepsin D
by Pawel Falkowski, Piotr Mrozek, Piotr Miluski, Zenon Lukaszewski and Ewa Gorodkiewicz
Biosensors 2022, 12(1), 21; https://doi.org/10.3390/bios12010021 - 31 Dec 2021
Cited by 5 | Viewed by 1591
Abstract
Non-fluidic array SPR imaging (SPRi) with appropriate biosensors is a new tool for the determination of various biomarkers in body fluids. Numerous biomarkers can be determined without signal enhancement or preliminarily preconcentration. The introduction of a new material solution of the chip may [...] Read more.
Non-fluidic array SPR imaging (SPRi) with appropriate biosensors is a new tool for the determination of various biomarkers in body fluids. Numerous biomarkers can be determined without signal enhancement or preliminarily preconcentration. The introduction of a new material solution of the chip may increase the scope of the application of this technique. Solutions with adhesive separating foil and an Ag/Au chip were compared with the previously used two-paint separating polymer and pure gold chip. These solutions were tested using the example of a biosensor for cathepsin D (Cath D), which consisted of pepstatin A (a Cath D inhibitor) immobilized via a cysteamine linker using the NHS/EDC protocol. Four material versions of the Cath D biosensor proved adequate in terms of range of linearity, LOQ, precision and recovery. All four versions of the biosensor were used for the determination of Cath D in the blood serum patients with glioblastoma and control samples, producing very similar results and showing an elevated biomarker concentration in the case of cancer. Therefore, the problem of determining the correct level of Cath D in the serum of healthy individuals has been resolved, correcting literature data which ranged over three orders of magnitude. Full article
(This article belongs to the Special Issue Liquid Biopsy with Surface Plasmon Resonance Biosensors)
Show Figures

Figure 1

11 pages, 2536 KiB  
Communication
An Immunosensor for the Determination of Cathepsin S in Blood Plasma by Array SPRi—A Comparison of Analytical Properties of Silver–Gold and Pure Gold Chips
by Pawel Falkowski, Piotr Mrozek, Zenon Lukaszewski, Lukasz Oldak and Ewa Gorodkiewicz
Biosensors 2021, 11(9), 298; https://doi.org/10.3390/bios11090298 - 27 Aug 2021
Cited by 10 | Viewed by 2053
Abstract
The array SPR imaging (SPRi) technique is well suited to the determination of biomarkers in body fluids, called liquid biopsy. No signal enhancement or analyte preconcentration is required. With the aim of achieving signal enhancement and lowering the cost of a single determination, [...] Read more.
The array SPR imaging (SPRi) technique is well suited to the determination of biomarkers in body fluids, called liquid biopsy. No signal enhancement or analyte preconcentration is required. With the aim of achieving signal enhancement and lowering the cost of a single determination, the replacement of gold-covered chips by silver–gold chips was investigated. The aim of this work was to investigate the analytical characteristics of a biosensor formed on a Ag/Au chip and to compare them with those of a biosensor formed on a gold chip. A biosensor for the determination of cathepsin S (Cath S) was chosen as an example. The biosensor consisted of the linker cysteamine and an immobilized rat monoclonal antibody specific for cathepsin S. Both biosensors exhibited a Langmuirian response to Cath S concentration, with linear response ranging from LOQ to 1.5 ng mL−1. The LOQ is 0.1 ng mL−1 for the biosensor formed on the Ag/Au chip, and 0.22 ng mL−1 for that formed on the gold chip. Recoveries and precision for medium and high Cath S concentrations were acceptable for both biosensors, i.e., precision better than 10% and recoveries within the range 102–105%. However, the results for the lowest Cath S concentration were better for the biosensor formed on the Ag/Au chip (9.4 and 106% for precision and recovery, respectively). Generally, no significant differences in analytical characteristics were observed between the Ag/Au and Au chips. The two biosensors were also compared in the determination of Cath S in real samples. Nine plasma samples from healthy donors and nine from patients with ovarian cancer were analyzed for Cath S concentration with the biosensors formed on Ag/Au and Au chips. The results obtained with the two biosensors were very similar and show no significant differences on the Bland–Altman plot. The Cath S concentration in the blood plasma of ovarian cancer patients was elevated by one order of magnitude as compared with the control (12.6 ± 3.6 vs. 1.6 ± 1.2 ng mL−1). Full article
(This article belongs to the Special Issue Liquid Biopsy with Surface Plasmon Resonance Biosensors)
Show Figures

Figure 1

Back to TopTop